NASDAQ:OXFD - Oxford Immunotec Global Stock Price, Forecast & News

Oxford Immunotec Global trades on the NASDAQ under the ticker symbol "OXFD."

Oxford Immunotec Global PLC (NASDAQ:OXFD) issued its earnings results on Tuesday, November, 5th. The company reported $0.04 earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.05) by $0.09. The firm had revenue of $21.20 million for the quarter, compared to analysts' expectations of $20.23 million. Oxford Immunotec Global had a net margin of 199.21% and a return on equity of 15.77%. The business's revenue was up 31.7% on a year-over-year basis. During the same quarter last year, the business earned ($0.13) earnings per share. View Oxford Immunotec Global's Earnings History.

Oxford Immunotec Global is scheduled to release their next quarterly earnings announcement on Monday, March 9th 2020. View Earnings Estimates for Oxford Immunotec Global.

2 equities research analysts have issued 12-month price targets for Oxford Immunotec Global's shares. Their forecasts range from $20.00 to $20.00. On average, they anticipate Oxford Immunotec Global's stock price to reach $20.00 in the next year. This suggests a possible upside of 19.4% from the stock's current price. View Analyst Price Targets for Oxford Immunotec Global.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Oxford Immunotec Global in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Oxford Immunotec Global.

Media headlines about OXFD stock have been trending somewhat positive recently, according to InfoTrie Sentiment. The research group identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Oxford Immunotec Global earned a news impact score of 1.0 on InfoTrie's scale. They also gave press coverage about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term. View News Stories for Oxford Immunotec Global.

Oxford Immunotec Global saw a decline in short interest in the month of December. As of December 31st, there was short interest totalling 411,000 shares, a decline of 9.6% from the December 15th total of 454,700 shares. Based on an average trading volume of 122,200 shares, the days-to-cover ratio is presently 3.4 days. Approximately 1.6% of the shares of the company are short sold. View Oxford Immunotec Global's Current Options Chain.

Some companies that are related to Oxford Immunotec Global include Heska (HSKA), Lantheus (LNTH), Intellia Therapeutics (NTLA), Quotient (QTNT), Meridian Bioscience (VIVO), Nymox Pharmaceutical (NYMX), Vermillion (VRML), ImmuCell (ICCC), Celldex Therapeutics (CLDX), Riot Blockchain (RIOT), Trinity Biotech (TRIB), Arca Biopharma (ABIO), GeneNews (GNWSF), Achieve Life Sciences (ACHV) and Akers Biosciences (AKER).

Based on aggregate information from My MarketBeat watchlists, some companies that other Oxford Immunotec Global investors own include AbbVie (ABBV), Immunomedics (IMMU), Halozyme Therapeutics (HALO), Intel (INTC), Sangamo Therapeutics (SGMO), Gold Resource (GORO), Adaptimmune Therapeutics (ADAP), Akorn (AKRX), Aptose Biosciences (APTO) and Fate Therapeutics (FATE).

Oxford Immunotec Global's stock is owned by a variety of of retail and institutional investors. Top institutional investors include Campbell & CO Investment Adviser LLC (0.14%). Company insiders that own Oxford Immunotec Global stock include Elizabeth M Keiley, Peter Wrighton-Smith and Richard A Sandberg. View Institutional Ownership Trends for Oxford Immunotec Global.

OXFD stock was bought by a variety of institutional investors in the last quarter, including Campbell & CO Investment Adviser LLC. View Insider Buying and Selling for Oxford Immunotec Global.

Shares of OXFD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of OXFD stock can currently be purchased for approximately $16.75.

Oxford Immunotec Global has a market capitalization of $442.99 million and generates $59.75 million in revenue each year. The company earns $120.78 million in net income (profit) each year or $0.51 on an earnings per share basis. Oxford Immunotec Global employs 215 workers across the globe.View Additional Information About Oxford Immunotec Global.

The official website for Oxford Immunotec Global is http://www.oxfordimmunotec.com/.

Oxford Immunotec Global's mailing address is 94C INNOVATION DRIVE MILTON PARK, ABINGDON X0, OX14 4RZ. The company can be reached via phone at 44-0-12-3544-2780 or via email at [email protected]